Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 12/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671495 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL29756947 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL15528142 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL1574005 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL3714541 | 0.79 | DAO (1.00) | DAOAURKAPARP1RIPK1 | |
| SCHEMBL668758 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL435130 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL13906225 | 0.78 | DAO (0.59) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL575029 | 0.77 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL22185856 | 0.76 | DAO (0.61) | DAOAURKAPARP1RIPK1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236130-B2 | Divalent nucleobase compounds and uses therefor | CARNEGIE MELLON UNIVERSITY (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200340044-A1 | Template-Directed Nucleic Acid Targeting Compounds | CARNEGIE MELLON UNIVERSITY | 2020-10-29 | — | — | US | disclosed |
| US-10370415-B2 | Divalent nucleobase compounds and uses therefor | CARNEGIE MELLON UNIVERSITY (US) | 2019-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236130-B2 | Divalent nucleobase compounds and uses therefor | DNTT, PNKP, GNA11 | DAO 3629/4885AURKA 3045/4885PARP1 195/4885 |
| US-20200340044-A1 | Template-Directed Nucleic Acid Targeting Compounds | TARDBP, HTT, TRDMT1 | DAO 1278/4885AURKA 1874/4885PARP1 677/4885 |
| US-10370415-B2 | Divalent nucleobase compounds and uses therefor | DNTT, POLM, POLL | DAO 2547/4885AURKA 3051/4885PARP1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.